Clinical Trials
Sep 02, 2026 · 1 min read · 26,365 views
Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal
L
Liam Turner
Editorial · Sep 02, 2026
Innovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The
← Previous
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
Next →
BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen
